(NASDAQ: COGT) Cogent Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 21.94%.
Cogent Biosciences's revenue in 2026 is $0.On average, 14 Wall Street analysts forecast COGT's revenue for 2026 to be $4,834,855,130, with the lowest COGT revenue forecast at $1,542,907,643, and the highest COGT revenue forecast at $8,212,177,057. On average, 13 Wall Street analysts forecast COGT's revenue for 2027 to be $61,912,699,389, with the lowest COGT revenue forecast at $21,679,589,087, and the highest COGT revenue forecast at $134,755,274,717.
In 2028, COGT is forecast to generate $123,223,233,056 in revenue, with the lowest revenue forecast at $66,170,059,738 and the highest revenue forecast at $168,638,863,980.